万孚生物
(300482)
| 流通市值：71.60亿 | | | 总市值：78.09亿 |
| 流通股本：4.29亿 | | | 总股本：4.68亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 1,038,506,474.79 | 581,742,751.09 | 2,086,830,072.65 | 1,690,175,392.8 |
| 营业总成本 | 924,188,328.32 | 491,970,446.34 | 2,249,566,528.36 | 1,602,538,044.34 |
| 其他经营收益 | | | | |
| 营业利润 | 142,567,604.25 | 97,917,656.29 | -110,415,843.1 | 129,743,948 |
| 利润总额 | 140,553,784.88 | 97,178,541.97 | -114,693,306.93 | 126,619,723.75 |
| 净利润 | 125,155,264.06 | 86,122,468.23 | -69,658,473.46 | 126,434,775.78 |
| 每股收益 | | | | |
| 其他综合收益 | 7,017,702.46 | 18,116,871.33 | 42,498,484.27 | -66,202.61 |
| 综合收益总额 | 132,172,966.52 | 104,239,339.56 | -27,159,989.19 | 126,368,573.17 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 3,775,264,539.97 | 3,456,884,307.57 | 3,301,305,228.24 | 3,275,266,911.17 |
| 非流动资产: | | | | |
| 非流动资产合计 | 2,965,382,068.98 | 3,277,283,824.7 | 3,300,371,989.71 | 3,377,247,419.33 |
| 资产总计 | 6,740,646,608.95 | 6,734,168,132.27 | 6,601,677,217.95 | 6,652,514,330.5 |
| 流动负债: | | | | |
| 流动负债合计 | 1,138,710,676.62 | 1,072,683,956.68 | 1,038,875,368.86 | 421,200,154.01 |
| 非流动负债: | | | | |
| 非流动负债合计 | 93,612,631.06 | 83,664,022.85 | 89,242,035.91 | 670,831,132.56 |
| 负债合计 | 1,232,323,307.68 | 1,156,347,979.53 | 1,128,117,404.77 | 1,092,031,286.57 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 5,446,757,020.89 | 5,517,163,417.51 | 5,414,625,996.42 | 5,500,455,052.07 |
| 股东权益合计 | 5,508,323,301.27 | 5,577,820,152.74 | 5,473,559,813.18 | 5,560,483,043.93 |
| 负债和股东权益合计 | 6,740,646,608.95 | 6,734,168,132.27 | 6,601,677,217.95 | 6,652,514,330.5 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 1,245,535,778.19 | 602,273,018.23 | 2,511,134,882.94 | 1,790,338,345.83 |
| 经营活动现金流出小计 | 821,537,415.07 | 384,103,290.17 | 2,048,097,322.09 | 1,737,629,150.11 |
| 经营活动产生的现金流量净额 | 423,998,363.12 | 218,169,728.06 | 463,037,560.85 | 52,709,195.72 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 2,827,353,191.68 | 1,607,461,222.84 | 4,661,584,129.73 | 3,616,239,150.52 |
| 投资活动现金流出小计 | 3,306,393,453.28 | 1,916,196,520.18 | 5,079,044,103 | 3,908,280,638.89 |
| 投资活动产生的现金流量净额 | -479,040,261.6 | -308,735,297.34 | -417,459,973.27 | -292,041,488.37 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 1,374,277.71 | 653,096.58 | 7,046,953.46 | 4,736,302.25 |
| 筹资活动现金流出小计 | 102,664,544.18 | 0 | 417,389,617.13 | 390,795,827.59 |
| 筹资活动产生的现金流量净额 | -101,290,266.47 | 653,096.58 | -410,342,663.67 | -386,059,525.34 |
| 汇率变动对现金及现金等价物的影响 | -3,606,874.27 | -1,385,935.36 | -1,339,102.5 | -266,391.73 |
| 现金及现金等价物净增加额 | -159,939,039.22 | -91,298,408.06 | -366,104,178.59 | -625,658,209.72 |
| 期末现金及现金等价物余额 | 302,059,810.84 | 370,700,442 | 461,998,850.06 | 202,444,818.93 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -159,939,039.22 | - | -366,104,178.59 | - |
最新报告期：2026-08-23| 研究机构 | 分析师 | 预测每股收益(元) | 更新日 |
| 2026年 | 2027年 | 2028年 |
| 华泰证券 | 代雯,高鹏 | 0.57 | 0.66 | 0.78 | 2026-08-23 |